Keyword: Ian Read

Ian Read stepped down as Pfizer's CEO in January, but the company is promising him a handsome payout for staying on board to counsel Albert Bourla.

Wondering how much incoming Pfizer CEO Albert Bourla is going to shake things up at the drugmaker? Not much, apparently.

Sen. Tammy Baldwin blasted Pfizer's plan to increase prices in January and called on the company to release details about its costs, plus more.

J&J CEO Alex Gorsky said Amazon could offer expertise in distribution as well as shake up reimbursement in a potential pharma entry.

Among small batch of price increases for the pharma giant was a 1.5% increase on superstar cancer drug Keytruda and 6% on HPV shot Gardasil.

Pfizer became the center of a drug pricing controversy this summer and delayed dozens of price hikes. Now it's ready to raise prices again in January.

A top pharma CEO says President Trump is right to say other countries benefit from higher U.S. drug prices, but he’s not sold on proposals for a fix.

There's been no shortage of drug pricing talk in recent weeks, and now Merck's and Pfizer's CEOs have had a chance to voice their thoughts.

Integration following a large-scale M&A is too much a distraction from Pfizer's "best pipeline in our history," said Bourla.

Big biopharma CEOs gave most or all their campaign contributions to Republicans this season, but one went full blue with his $120,000.